Fundraising FoxToronto · Seed–Growth · 17 people tracked
Also known as LUMIRA CAPITAL INVESTMENT MANAGEMENT INC.
Find your way into Lumira Ventures
Sign up to see every warm intro you have to Lumira Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lumira Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Lumira Ventures backs mission-driven entrepreneurs building transformative life sciences companies. The firm focuses on developing and commercializing impactful products aimed at improving outcomes for patients, positioning itself as a leading North American life sciences investor.
Source: firm website, verified Sep 29, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 55 of 72 portfolio companiesBiotech ×42Healthtech ×36Medical Devices ×27Digital Health ×14Deep Tech ×8Hardware ×6AI & Machine Learning ×3FemTech ×1
HQs:United States×33Canada×5United Kingdom×1
Who they back
founder profiles across 25 portfolio companiesFounding team size:solo founder×132 founders×73 founders×24+ founders×3
Where their founders studiedfrom 17 founders with education data
École de technologie supérieure ×2University of Toronto ×2
What their founders studiedfrom 20 founders with field-of-study data
Engineering ×10Life Sciences ×6Medicine ×5
Where their founders worked beforefrom 23 founders with career history
Dalhousie University ×3
10 founders hold a PhD · 1 hold an MBA (of 21 with degree data)
Investments · 72 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 22024 · 32023 · 32022 · 12021 · 22020 · 22019 · 42017 · 12016 · 12015 · 22014 · 226 dated
Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases.
BiotechHealthtechMarkham, US
Pardeep Nijhawan(Executive Officer, Director)Stephen Lemieux(Executive Officer)inMichael Brooks(Executive Officer)Mary Catherine Brisson(Executive Officer)Mark A. McPartland(Executive Officer)Kathi Niffenegger(Executive Officer)in
Co-investorsInveready Technology Investment GroupVenture Ontario
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)Partners ResoluteThynk CapitalAdvent Life SciencesOmega Funds+1 more
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsBrace PharmaCTI Life Sciences Fund L.P.HBM Healthcare InvestmentsNextech InvestWUTIF CapitalAmplitude Venture Capital
Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.
BiotechDigital HealthHealthtechMedical DevicesSammamish, US
Kent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)
Board seatGerry Brunk· per SEC Form D
Co-investorsJAZZ Venture PartnersAngelini VenturesF-Prime CapitalIaso VenturesMayo Clinic Ventures
SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.
AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US
Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in
Board seatGerry Brunk· per SEC Form D
Co-investorsS3 VenturesSV Health InvestorsDeerfield Management CompanyJohnson & Johnson Innovation – JJDC
Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.
BiotechDeep TechMedical DevicesSan Diego, US
Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))inRaymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in
Co-investorsRevelation PartnersSR One Capital Management
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.
BiotechHealthtech
Co-investorsAlpha Wave GlobalRoche Venture FundAngelini VenturesJDRF T1D Fund
Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste.
BiotechDigital HealthHealthtechMedical DevicesDelray Beach, US
Rick Geoffrion(Founder, President and CEO & Board Member)in
Co-investorsRemiges Ventures, Inc.DeepWork CapitalFlorida Opportunity Fund
Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.
BiotechHealthtechMedical Devices
Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinAmy Sehnertin
Co-investorsAmzak HealthadMare BioInnovationsAlexandriaCTI Life Sciences Fund L.P.
Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.
HardwareHealthtechMedical DevicesMontreal
Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFrançois Trudeau(Co-founder & CTO, Board Director)inPhilippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)inMaxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)inYves-Antoine Crête(Co-founder (Phase 2) & VP Technical R&D and Operations)inGabriel Georges(Co-founder & Clinical Advisor)in
Co-investorsBroadview VenturesAjax HealthDesjardins CapitalBoreal VenturesCathexis VenturesFront Row Ventures+3 more
Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).
BiotechDigital HealthMedical Devices
Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra Odink(President & Chief Development Officer)inAmy Sehnert(Chief Medical Officer)inMatt Killeen(Chief Business Officer)in
BoardSaumya Das(Chief Scientific Advisor)
Co-investorsadMare BioInnovationsAmzak HealthCTI Life Sciences Fund L.P.Fonds de solidarité FTQ
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Founder and Advisor (Board Observer))Todd Rosengart(Founder; Board Observer)John Tucker(President and CEO)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)inJames Cohen(Director)
Co-investorsFountain Healthcare PartnersJeito CapitalLongwood FundSofinnova Ventures
Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.
BiotechTewksbury, US
George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)
BoardPaul LaViolette(Director)inKevin Gillis(Director)inGerald Brunk(Director)inIrit Yaniv(Director)in
Board seatGerry Brunk· per SEC Form D
Co-investorsAccelmed PartnersGeneral CatalystSV Health InvestorsThird Rock Ventures
.png)
Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.
HealthtechWashington, US
Richard Geoffrion(Executive Officer, Director)Robert Henkin(Director)
BoardTakahide Koda(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsRemiges Ventures, Inc.DeepWork CapitalFlorida Opportunity Fund
Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.
Digital HealthHealthtechMedical DevicesWoodridge, US
Harry Rowland(Executive Officer, Director)inAnthony Nunez(Founder)in
BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)Sam R. Leno(Director)Leslie A. Saxon(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsAPERTURE Venture PartnersBioventures InvestorsJumpstart VenturesOSF VenturesSeroba Life SciencesSV Health Investors+1 more
Company whose formation and launch the LifeSci team supported.
BiotechHealthtechSummit, US
Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)inOrrin Devinsky(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsLifeSci Venture PartnersRed Tree Venture
Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.
HardwareHealthtechMedical DevicesMarkham, CA
Harold Wodlinger(Director)inRandy AuCoin(President & CEO)inRob Sandler(Executive Officer)inJerrold Wen(Executive Officer)in
BoardWilliam Wortman(Director)Gaston Matthyssens(Director)
Board seatPeter van der Velden· per SEC Form D
Co-investorsiGan PartnersPMVVenture OntarioVesalius Biocapital Partners
HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.
BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB
Thomas Davison(Executive Officer, Director)inM. Christine Gibbons(Executive Officer, Director)inWen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)
Board seatGerry Brunk· per SEC Form D
Co-investorsAlpha Wave GlobalAmzak HealthArboretum VenturesEarly Stage Partners, LPHealthQuest CapitalK5 Global+7 more
Medexus Pharmaceuticals is a specialty pharmaceutical company focused on orphan drugs and rare disease treatments, with a portfolio of specialty and rare disease products.
BiotechHealthtechToronto, CA
Ken d'Entremont(Executive Officer, Director)inRoland Boivin(Executive Officer)Terri Shoemaker(Executive Officer)
BoardStephen Nelson(Director)Adele Gulfo(Director)
Board seatPeter van der Velden· per SEC Form D
BiotechBoston, US
Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)in
Board seatGerry Brunk· per SEC Form D · $35M raise · filed Oct 2022
Co-investorsAdvent Life SciencesOrbiMed
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD.
BiotechHealthtech
C Vivek Lal(Founder & CSO)inAmit Gaggar(Chief Medical Officer)inGaurav Mehta(CEO)in
AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells.
BiotechDigital HealthMedical DevicesToronto, CA
Mike Cooke(Co-Founder & CEO)inMolly Shoichet(Co-Founder & Chief Science Officer)
Co-investorsInveready Technology Investment GroupNorthspring Capital PartnersStand Up VenturesToronto Innovation Acceleration PartnersMBX Capital
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGV (Google Ventures)HBM Healthcare Investments+6 more
Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.
BiotechDigital HealthHealthtechMedical DevicesVictoria, US
Richard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)
BoardKurt von Emster(Director)in
Co-investorsNew Enterprise Associates (NEA)venBio Partners
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsSofinnova VenturesvenBio PartnersMRL Ventures FundCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+8 more
BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.
Digital HealthHealthtechMedical DevicesSeattle, US
Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)
Co-investorsAPERTURE Venture PartnersAphelion CapitalAscension VenturesRC CapitalRex Health VenturesSV Health Investors+2 more
Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections.
BiotechDeep TechToronto, CA
Leah Cowen(Co-founder & CSO)Luke Whitesell(Co-founder & Consultant)Dominic Jaikaran(President & CEO)in
Co-investorsToronto Innovation Acceleration Partners
Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.
BiotechHealthtechMedical DevicesKirkland, US
Frederick A. Stewart(Executive Officer, Director)Rick Wypych(Executive Officer)in
BoardKurt Wheeler(Director)Nathan Every(Director)Douglas C. Fisher(Director)Gerry Brunk(Director)in
Co-investorsAPERTURE Venture PartnersRedbus VenturesAlly Bridge GroupClaret Capital PartnersJefferiesM.H. Carnegie & Co.
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.
AI & Machine LearningBiotechDeep Tech
Clarissa Desjardins(Founder)in
Co-investorsOrbiMedAlexandriaDIMENSIONAngelini VenturesBDC Thrive Venture Fund for WomenAmplitude Venture Capital+1 more
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.
BiotechDigital HealthMedical DevicesCharlottesville, US
Kevin Eisenfrats(Founder)inJohn Herr(Founder)
BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)
Co-investorsBiotechnology Value FundMBX CapitalAllied Venture PartnersAlumni VenturesAmboy Street VenturesAurum Venture Partners+17 more
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalMenlo Ventures+5 more
Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsAngelini VenturesNoeticToronto Innovation Acceleration Partners
BiotechGermantown, US
John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)
Co-investorsATEM Capital FundPlains VenturesEcho Investment CapitalLeaps by BayerMPM BioImpact
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.
Digital HealthHealthtechMedical DevicesMinneapolis, US
Stacey Pugh(Leadership (CEO))inChris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMelanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in
Co-investorsArboretum VenturesHatteras Venture PartnersIntuitive VenturesLongitude CapitalSoutheast Minnesota Capital Fund
enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.
BiotechMedical Devices
Co-investorsCTI Life Sciences Fund L.P.
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapPivotal Life SciencesSeroba Life SciencesVenture OntarioYsios Capital+6 more
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)
Co-investorsMountain Group CapitalRA CapitalSolasta VenturesHatteras Venture Partners
Cytek Biosciences develops full spectrum (spectral) flow cytometry instruments, reagents, and software tools for researchers, enabling large multicolor panels of 40 colors and beyond from a single sample tube.
BiotechHardwareHealthtechBellevue, US
Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway.
BiotechHealthtech
Rahul Aras(Chief Executive Officer)inOvid Trifan(Chief Medical Officer)inSteve Horrigan(Chief Scientific Officer)in
Co-investorsGreen Park & Golf VenturesPortal Innovations
KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases.
AI & Machine LearningBiotechDeep Tech
Co-investorsRemiges Ventures, Inc.
Developed a robotic surgical arm for knee and hip arthroplasty; acquired by Stryker for $1.65B in 2013.
Co-investorsAPERTURE Venture PartnersMontreux Equity Partners
Nervonik develops peripheral nerve stimulation (PNS) systems designed for high-motion, dynamic activity, using a patented technology that adds biosensing and objective feedback to neuromodulation.
HardwareHealthtechMedical Devices
Co-investorsFoothill VenturesJoyance PartnersShangBay Capital LLCUS Venture PartnersAmzak HealthU.S. Venture Partners
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(President and Chief Executive Officer)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Co-investorsCanaan PartnersF-Prime CapitalMission BiocapitalMonograph Capital PartnersOUP (Osage University Partners)
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsXeraya CapitalB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment Partners+1 more
.jpeg){kind=logo}
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)
Co-investorsOUP (Osage University Partners)Vivo CapitalWellington ManagementRA CapitalRed Tree VentureSBI Investment
SoundBlade Medical develops handheld histotripsy technology for non-invasive surgery, using focused ultrasound to treat tissue with precision.
HardwareHealthtechMedical Devices
Jeremy Brown(Co-Founder & CTO)inMatt Mallay(Co-Founder & Sr. Dir. R&D)inAndre Bezanson(Co-Founder & Dir. R&D)inEli Vlaisavljevich(Co-Founder)inRick Balys(Co-Founder)inNeil Barman(Chief Executive Officer)in
Co-investorsAmzak HealthAPERTURE Venture PartnersInvest Nova Scotia
Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats.
BiotechDeep TechHealthtech
HealthtechSunnyvale, US
Thomas Afzal(Executive Officer, Director)
BoardPeter van der Velden(Director)inDavid Milne(Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
Co-investorsHLM Investment PartnersSV Health InvestorsSV Life Sciences
Think Research works with health systems to improve care delivery through clinical software, clinical expertise, and hands-on operational support across access to care, clinical workflow, and medication safety.
Digital HealthHealthtechSaaS
Co-investorsiGan Partners
Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.
BiotechHealthtechLongevitySan Diego, US
Dennis Podlesak(Executive Officer, Director)Lynne R. Rollins(Executive Officer)Eckard Weber, MD(Executive Officer, Director)Eckard Weber, M.D.(Executive Officer, Director)in
BoardDaniel Hetu, MD, MBA(Director)Brent Ahrens(Director)in
Co-investorsCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CeltaxsysGenEpArclight TherapeuticsAssertiotxBauschCeption TherapeuticsCorus PharmaceuticalsDepomedESSA PharmaceuticalsForbiusGladius PharmaceuticalsISTA PharmaceuticalsKaipharmaceuticalsMorphotekNavionPharmassetResonantmedicalThryv TherapeuticsU-Systems
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
3 IPOs · 3 acquisitions · showing 5Edesa BiotechNASDAQ: EDSAX4 PharmaNASDAQ: XFORZymeworksNASDAQ: ZYMEGuavatechnologiesacq. by Cytek BiosciencesU-Systemsacq. by GE Healthcare
Portfolio news
latest coverage across their companiesEdesa Biotech · stocktitan.net · Jul 14, 2026
Nervonik · citybiz.co · Apr 28, 2026
Endogenex · endogenex.com · Mar 26, 2026
Nocion Therapeutics · nociontx.com · Mar 20, 2026
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2024
Disclosed stake · filed Jan 2023
Disclosed stake · filed Jan 2020
Disclosed stake · filed Sep 2019
Disclosed stake · filed Aug 2019
Disclosed stake · filed Jun 2019
Disclosed stake · filed Feb 2018
Disclosed stake · filed Apr 2017
8 insider ownership filings (Forms 3/4/5)
at enGene Holdings Inc. (ENGN), Edesa Biotech, Inc. (EDSA)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Lumira Ventures made?
- Lumira Ventures has 72 tracked investments, 6 of which have exited, including 7 dated in the last 24 months.
- What stage does Lumira Ventures invest at?
- Lumira Ventures invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Lumira Ventures's typical check size?
- Lumira Ventures typically writes checks of $1M – $10M.
- What sectors does Lumira Ventures focus on?
- Lumira Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Lumira Ventures located?
- Lumira Ventures is headquartered in Toronto, CA.
- Who does Lumira Ventures co-invest with?
- Lumira Ventures most often shares deals with Angelini Ventures, APERTURE Venture Partners, SV Health Investors, among 129 tracked co-investors.
Images
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.